Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 306

Study on the Effects of Volrustomig and Drug Combination for Patients with Advanced Hepatobiliary Cancer

Study on the Effects of Volrustomig and Drug Combination for Patients with Advanced Hepatobiliary Cancer

Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Study of Pembrolizumab with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative

Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative

Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Continued Treatment Study for Adults with Advanced Cancer Using Pemigatinib

Continued Treatment Study for Adults with Advanced Cancer Using Pemigatinib

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Study on Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Early and Metastatic Triple Negative Breast Cancer

Study on Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Early and Metastatic Triple Negative Breast Cancer